UWS
ATOS icon

Unique Wealth Strategies’s Atossa Therapeutics ATOS Stock Holding History

Unique Wealth Strategies’s Portfolio ATOS Stock Details ATOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-11
Closed -$299 – 244
2024
Q2 		$299 Buy
+11
New +$243 ﹤0.01% 634

Other funds holding ATOS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Unique Wealth Strategies's ATOS Position: Q3 2024 in Review

Unique Wealth Strategies sold out of Atossa Therapeutics (ATOS) in Q3 2024, closing a stake of 11 shares — an estimated $299 sold.

Unique Wealth Strategies first reported a position in ATOS in Q2 2024 and held it in 1 quarter. The position peaked at $299 in Q2 2024. 86 funds tracked by Wall St. Rank hold ATOS as of Q3 2024.

  • Unique Wealth Strategies reported no remaining Atossa Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Unique Wealth Strategies sold 11 Atossa Therapeutics shares in Q3 2024, an estimated $299.
  • Unique Wealth Strategies first reported a position in Atossa Therapeutics in Q2 2024 and held it in 1 quarter.
  • Unique Wealth Strategies's Atossa Therapeutics position peaked at $299 in Q2 2024.
  • 86 funds tracked by Wall St. Rank held Atossa Therapeutics as of Q3 2024.

Based on Unique Wealth Strategies's 13F filing for Q3 2024, filed 14 Jul 2026.